Cerebrolysin vs Pinealon
Both Cerebrolysin and Pinealon are used for cognitive. Here's how their evidence, dosing, and regulatory status actually compare.
Cerebrolysin
Evidence BCerebrolysin (porcine brain peptide complex)
A standardized mixture of low-molecular-weight peptides from porcine brain. Decades of stroke, dementia, and TBI trial data — modest but consistent cognitive recovery effects.
View full Cerebrolysin profile →Pinealon
Evidence CPinealon (EDR)
A short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.
View full Pinealon profile →Side-by-Side
| Attribute | Cerebrolysin | Pinealon |
|---|---|---|
| Evidence Grade | B | C |
| FDA Status | Not FDA-approved in US — approved in 50+ countries for stroke, traumatic brain injury, and dementia | Not FDA-approved — Russian-origin research peptide |
| Typical Dose | Trial range: 5–30 mL daily (intravenous infusion) | 5–10 mg daily for 10–20 days (subcutaneous, cycled) |
| Clinics Indexed | 41 | 9 |
| Categories | cognitive, neuroprotection | cognitive, longevity |
Key reported benefits — Cerebrolysin
- ✓Stroke recovery support
- ✓TBI rehabilitation
- ✓Cognitive function in dementia
Key reported benefits — Pinealon
- ✓Cognitive function (preclinical)
- ✓Reduced oxidative damage
- ✓Sleep/circadian effects
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.